Somatrogon - OPKO Health

Drug Profile

Somatrogon - OPKO Health

Alternative Names: hGH-CTP; Human growth hormone-CTP; Lagova; MOD-4023; PF-06836922; Somatropin long-acting - OPKO Health

Latest Information Update: 11 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Modigene
  • Developer OPKO Health
  • Class Biological proteins; Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity No

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 16 Jun 2017 Efficacy data from a phase III trial in Somatropin deficiency released by OPKO Health
  • 16 Jun 2017 OPKO Health plans a clinical trial for Somatropin deficiency (In children) in Japan
  • 16 Jun 2017 OPKO Health plans open-label extension trials for the phase III (In adults) and phase II (In children) trials for Somatropin deficiency
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top